ChinaBio Today -- China Sky One Medical has bought a proprietary breast lesion drug from Harbin Medical University for 10 million RMB ($1.5 million). The drug, which China Sky One and Harbin developed jointly, has completed its Phase I trial. In the more than 10,000 patients enrolled in the test, the drug was 100% effective with an 89% curability rate. China Sky One said that final SFDA approval for the drug is about two to three years in the future.
